MetaVia Announces Positive Interim Phase 1 Data for DA-1726

Nov 7, 2026, 9:31 AM ETTrialRead the original at prnewswire.com

Good for MTVA

MetaVia's interim Phase 1 data showed lower body weight, liver fat, and HbA1c versus placebo, supporting DA-1726's development. The results are early, and the Phase 2 study is planned for the second half of 2027.

MTVA · MetaVia Inc.

AI read · Good for MTVA

The AI's read

These results give an early human sign that DA-1726 may help with weight and liver fat. That could support its development. But this was a Phase 1 study, and the next study is planned for the second half of 2027. The findings are encouraging, but much testing remains.

Get alerts for MTVA

Follow MetaVia Inc. (MTVA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MTVA

Free on the App Store and Google Play, or on the web.